

Effects of Glutamine on Glycemic Control During and After Exercise in Adolescents With Type 1 Diabetes

A pilot study

NELLY MAURAS, MD¹
DONGYUAN XING, PHD²
LARRY A. FOX, MD¹

KIM ENGLERT, RN¹
DOMINIQUE DARMAUN, MD, PHD¹

Design

Regular dietary intake was maintained for at least 3 days prior to each admission to the clinical research center (CRC) and diabetes was managed as routine. Subjects were admitted mid-day, an intravenous line was placed, and blood glucose was titrated (mid 100 mg/dl) prior to 3:00 P.M. exercise. Children were randomized to receive a drink containing glutamine or placebo (PL, calorie- and nitrogen-free) before exercise and at bedtime (0.25 g/kg/dose). Patients and CRC staff were blinded to the type of drinks consumed. Sessions consisted of four 15-min treadmill cycles (heart rate ~140 bpm) with 5-min rest breaks when blood glucose concentrations were checked for a total of 75 min. If blood glucose was <60 mg/dl, subjects consumed 15–30 g of carbohydrate and were not allowed back on the treadmill until blood >70 mg/dl. Insulin basal rates were continued during exercise. Afterward, subjects ate a snack and then dinner. Blood glucose was monitored hourly overnight from 8:00 P.M. to 8:00 A.M. Blood glucose ≤60 mg/dl prompted treatment with an oral carbohydrate; treatment was repeated as needed until >80 mg/dl. Fasting glutamine and ammonia concentrations were measured 16-h post-exercise the following morning. Subjects were discharged after breakfast and returned within 3 weeks for an identical study with either placebo or glutamine. The caloric/protein intake of the two CRC days was identical; visits were randomized crossover.

Assays

Blood glucose concentrations were measured with a Freestyle meter (Abbott Diabetes Care, Alameda, CA) and by glucose oxidase methods with a Beckman glucose analyzer (Beckman, Brea, CA). Plasma glutamine concentrations were measured by gas chromatography–mass spectrometry and ammonia using an automated chemistry analyzer.

OBJECTIVE — To investigate if oral glutamine ameliorates exercise and postexercise nighttime hypoglycemia in type 1 diabetic adolescents.

RESEARCH DESIGN AND METHODS — Ten adolescents (15.2 ± 1.4 years [SD], A1C 6.9 ± 0.9%) on insulin pumps were studied. The subjects were randomized to receive a glutamine or placebo drink pre-exercise and at bedtime (0.25 g/kg/dose). A 3:00 P.M. exercise session consisted of four 15-min treadmill/5-min rest cycles. Pre-exercise blood glucose was 140–150 mg/dl and was monitored throughout the night. Studies were randomized crossover over 3 weeks.

RESULTS — Blood glucose levels dropped comparably (52%) during exercise on both days. However, the overnight number of hypoglycemic events was higher on glutamine than placebo (≤70 mg/dl, $P = 0.03$ and ≤60, $P = 0.05$). The cumulative probability of nighttime hypoglycemia was increased on glutamine days (80%) versus placebo days (50%) ($P = 0.02$).

CONCLUSIONS — Glutamine increased the cumulative probability of postexercise overnight hypoglycemia compared with placebo in adolescents with type 1 diabetes. Whether glutamine may enhance insulin sensitivity postexercise requires further study in type 1 diabetes.

Diabetes Care 33:1951–1953, 2010

We observed a higher incidence of hypoglycemia during exercise and during the night following exercise versus after a sedentary day in adolescents with type 1 diabetes (1,2). Although hypoglycemia decreased by discontinuing the insulin pump during exercise, significant rebound hyperglycemia was observed (3).

Glutamine, the body's most abundant free amino acid, is thought to regulate intestinal protein synthesis and be a major source of carbon for gluconeogenesis (4). However, conflicting reported data suggest it can impair or accelerate recovery from hypoglycemia (5–7). In this pilot study we investigated if oral glutamine

could ameliorate hypoglycemia during exercise and in the nighttime after exercise in children with type 1 diabetes.

RESEARCH DESIGN AND METHODS

Written consent was obtained after approval by the Wolfson Children's Hospital Institutional Review Committee. Ten adolescents (five boys and five girls; mean [SD] age 15.2 ± 1.4 years) with type 1 diabetes on insulin pump therapy were recruited. Mean diabetes duration was 6.2 ± 3.3 years; A1C, 6.9 ± 0.9%; with normal BMI, 76.9 ± 12.2 percentile. Subjects were on no other medications or dietary supplements.

From the ¹Division of Endocrinology, Diabetes and Metabolism, Nemours Children's Clinic, Jacksonville, Florida; and the ²Jaeb Center for Health Research, Tampa, Florida.

Corresponding author: Nelly Mauras, nmauras@nemours.org.

Received 11 February 2010 and accepted 19 June 2010. Published ahead of print at <http://care.diabetesjournals.org> on 28 June 2010. DOI: 10.2337/dc10-0275.

© 2010 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Statistics

During exercise, hypoglycemia was considered if blood glucose was ≤ 70 mg/dl; if treated, the most recent previous blood glucose was carried forward 1 h in the calculations. Repeated-measures regression models were performed to compare glutamine concentrations and glucose values prior to exercise and the percentage drop during exercise, the overnight mean glucose, and the percentage of the hypoglycemic values of each visit. Rank scores (van der Waerden) were used to normalize skewed distributions. The proportions of subjects developing hypoglycemia during exercise on both visits were compared using a permutation test as was the time from 10:00 P.M. until the first laboratory glucose value ≤ 70 mg/dl on the 2 days; all analyses were controlled for a visit effect. SAS version 9.1 (SAS Institute, Cary, NC) and two-sided *t* tests were used.

RESULTS — Plasma glutamine concentrations were $>50\%$ higher the morning after glutamine administration ($316 \mu\text{mol/l}$) as compared with placebo ($200 \mu\text{mol/l}$, $P < 0.001$).

Exercise

Mean blood glucose concentrations prior to exercise were comparable on the glutamine and placebo day (143 ± 31 mg/dl vs. 162 ± 54 , respectively; $P = 0.44$) with a similar percentage drop from baseline during exercise of $52 \pm 15\%$ glutamine versus $52\% \pm 9\%$ placebo ($P = 0.84$). There was a comparable number of subjects that developed hypoglycemia during exercise on the glutamine ($n = 6$) or placebo day ($n = 7$).

Overnight

Mean nighttime postexercise low-glucose levels (≤ 70 mg/dl or ≤ 60 mg/dl) were more frequent after glutamine than after placebo (≤ 70 mg/dl: glutamine, 19%; placebo, 15%; $P = 0.03$; and ≤ 60 mg/dl: glutamine, 7.7%; placebo, 3.6%; $P = 0.05$). The cumulative probability of overnight hypoglycemia was increased on the glutamine day (80%) compared with the placebo day (50%, $P = 0.02$) (Fig. 1).

Safety

Glutamine is tasteless and odorless, so it was well tolerated. Plasma ammonia concentrations the morning after the studies were similar (glutamine: $40.2 \pm 15.3 \mu\text{mol/l}$; placebo: $41.2 \pm 16.1 \mu\text{mol/l}$, $P = \text{NS}$).




Figure 1—Cumulative probability of nighttime hypoglycemia (≤ 70 mg/dl) if the same adolescents with type 1 diabetes took glutamine or placebo before afternoon exercise and at bedtime.

CONCLUSIONS — The pilot study data suggest that glutamine supplementation increases the likelihood of nighttime hypoglycemia in adolescents with type 1 diabetes after performing heavy exercise.

Morning glutamine concentrations 16-h post-exercise were $>50\%$ higher during the glutamine day versus the placebo day, however these concentrations were still below normal compared with healthy, age-matched control subjects or adolescents with type 1 diabetes measured at rest ($P < 0.001$) (8) and similar to those of healthy adults after prolonged exercise (9). It is possible that glutamine is low due to increased use in gluconeogenesis or use as a buffer or due to increased cortisol secretion, which enhances splanchnic glutamine utilization (10). This relative glutamine depletion after exercise requires further study.

In our study, glutamine did not affect blood glucose levels during exercise but increased the cumulative probability of nighttime hypoglycemia post-exercise. Indirect evidence suggests glutamine may indeed enhance insulin sensitivity in other experimental and clinical situations associated with insulin resistance including in the intensive care unit with trauma patients (11,12) and in children with cystic fibrosis on growth hormone (13). Glutamine increased insulin signaling/sensitivity in skeletal muscle in experimental animals (14), and oral glutamine increased nonoxidative glucose disposal in healthy exercising subjects (15).

Our pilot study, however, has several

limitations including its small sample size, the low concentrations of glutamine achieved, and no direct measurement of insulin sensitivity. These results are nonetheless intriguing as the investigation of nutritional, nonpharmacological avenues to improve diabetes control is important and deserves further study, particularly in teenagers who have increased insulin resistance. In the aggregate, these data are congruent with the positive effect of glutamine on insulin sensitivity.

In conclusion, oral glutamine administration was associated with a higher incidence of nighttime post-exercise hypoglycemia as compared with placebo in a pilot group of adolescents with type 1 diabetes. Whether glutamine supplementation affects peripheral and/or hepatic insulin sensitivity requires further study in children with type 1 diabetes.

Acknowledgments — This work was funded by grants from the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development: U10HD041918-06 (to N.M.) and HD041906-02 (to D.X.).

No potential conflicts of interest relevant to this article were reported.

N.M. is the principal investigator of the studies. She wrote the grant, recruited the subjects, carried out the experiments, analyzed the data, and wrote the paper. D.X. is the principal biostatistician of the study and helped analyze the data and create the graphs and wrote the statistical section. L.A.F. is a co-investigator and helped recruit and treat the

patients in the CRC and reviewed and critiqued the manuscript. K.E. is the lead study coordinator in charge of all implementation aspects of the study. D.D. is a co-investigator who assisted N.M. in grant writing, data analysis and interpretation and assisted in the writing of the paper.

Parts of this study were presented in abstract form at the 69th Scientific Sessions of the American Diabetes Association, New Orleans, Louisiana, 5–9 June 2009.

The authors are grateful to Shawn Sweeten for laboratory technical assistance and to Shiela Smith and the expert nursing staff of the Wolfson Children's Hospital CRC for the expert care of our subjects.

References

1. Tansey MJ, Tsalikian E, Beck RW, Mauras N, Buckingham BA, Weinzimer SA, Janz KF, Kollman C, Xing D, Ruedy KJ, Steffes MW, Borland TM, Singh RJ, Tamborlane WV, Diabetes Research in Children Network (DirecNet) Study Group. The effects of aerobic exercise on glucose and counterregulatory hormone concentrations in children with type 1 diabetes. *Diabetes Care* 2006;29:20–25
2. Tsalikian E, Mauras N, Beck RW, Tamborlane WV, Janz KF, Chase HP, Wysocki T, Weinzimer SA, Buckingham BA, Kollman C, Xing D, Ruedy KJ, Diabetes Research in Children Network (DirecNet) Study Group. Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus. *J Pediatr* 2005;147:528–534
3. Diabetes Research in Children Network (DirecNet) Study Group, Tsalikian E, Kollman C, Tamborlane WB, Beck RW, Fiallo-Scharer R, Fox L, Janz KF, Ruedy KJ, Wilson D, Xing D, Weinzimer SA. Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. *Diabetes Care* 2006;29:2200–2204
4. Hankard RG, Haymond MW, Darmaun D. Role of glutamine as a glucose precursor in fasting humans. *Diabetes* 1997;46:1535–1541
5. Battezzati A, Benedini S, Fattorini A, Piceni Sereni L, Luzi L. Effect of hypoglycemia on amino acid and protein metabolism in healthy humans. *Diabetes* 2000;49:1543–1551
6. Souza HM, Borba-Murad GR, Curi R, Galletto R, Bazotte RB. Combined administration of glucose precursors is more efficient than that of glucose itself in recovery from hypoglycemia. *Res Commun Mol Pathol Pharmacol* 2001;110:264–272
7. Garcia RF, Gazola VA, Barrena HC, Hartmann EM, Berti J, Toyama MH, Boschero AC, Carneiro EM, Manso FC, Bazotte RB. Blood amino acids concentration during insulin induced hypoglycemia in rats: the role of alanine and glutamine in glucose recovery. *Amino Acids* 2007;33:151–155
8. Hankard RG, Haymond MW, Darmaun D. Role of glucose in the regulation of glutamine metabolism in health and in type 1 insulin-dependent diabetes. *Am J Physiol Endocrinol Metab* 2000;279:E608–E613
9. Gleeson M. Dosing and efficacy of glutamine supplementation in human exercise and sport training. *J Nutr* 2008;138:2045S–2049S
10. Thibault R, Welch S, Mauras N, Sager B, Altomare A, Haymond M, Darmaun D. Corticosteroids increase glutamine utilization in human splanchnic bed. *Am J Physiol Gastrointest Liver Physiol* 2008;294:G548–G553
11. Déchelotte P, Hasselmann M, Cynober L, Allaouchiche B, Coëffier M, Hecketsweiler B, Merle V, Mazerolles M, Samba D, Guillou YM, Petit J, Mansoor O, Colas G, Cohendy R, Barnoud D, Czernichow P, Bleichner G. L-alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: the French controlled, randomized, double-blind, multicenter study. *Crit Care Med* 2006;34:598–604
12. Bakalar B, Duska F, Pacht J, Fric M, Otahal M, Pazout J, Andel M. Parenterally administered dipeptide alanyl-glutamine prevents worsening of insulin sensitivity in multiple-trauma patients. *Crit Care Med* 2006;34:381–386
13. Darmaun D, Hayes V, Schaeffer D, Welch S, Mauras N. Effects of glutamine and recombinant human growth hormone on protein metabolism in prepubertal children with cystic fibrosis. *J Clin Endocrinol Metab* 2004;89:1146–1152
14. Prada PO, Hirabara SM, de Souza CT, Schenka AA, Zecchin HG, Vassallo J, Velloso LA, Carneiro E, Carvalheira JB, Curi R, Saad MJ. L-glutamine supplementation induces insulin resistance in adipose tissue and improves insulin signalling in liver and muscle of rats with diet-induced obesity. *Diabetologia* 2007;50:1949–1959
15. Bowtell JL, Gelly K, Jackman ML, Patel A, Simeoni M, Rennie MJ. Effect of oral glutamine on whole body carbohydrate storage during recovery from exhaustive exercise. *J Appl Physiol* 1999;86:1770–1777